sars-cov-2 rs
Vaccineexperimental
Clinical trial activity
12 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
8
Phase 3
7
Phase 4
1
Earliest trial started May 6, 2020 (NCT04368988)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07086222 | Phase 4 | Nov 10, 2025 | Novavax |
| NCT07079670 | Phase 3 | Oct 16, 2025 | Novavax |
| NCT06482359 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2024 | Novavax |
| NCT06291857 | Phase 3 | Oct 21, 2024 | Novavax |
| NCT06409663 | Phase 2/Phase 3 (Phase 3) | Aug 5, 2024 | Novavax |
| NCT05875701 | Phase 3 | Mar 28, 2023 | Novavax |
| NCT05519839 | Phase 2 | Jan 16, 2023 | Novavax |
| NCT04961541 | Phase 1/Phase 2 (Phase 2) | Sep 8, 2021 | Novavax |
| NCT04611802 | Phase 3 | Dec 27, 2020 | Department of Health and Human Services, Novavax |
| NCT04583995 | Phase 3 | Sep 28, 2020 | Novavax, University of London |
| NCT04533399 | Phase 2 | Aug 17, 2020 | Bill and Melinda Gates Foundation, Novavax, University of the Witwatersrand |
| NCT04368988 | Phase 1 | May 6, 2020 | Novavax |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novavax | For profit | 12 | 12 | 4 | 2020 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2020 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of the Witwatersrand | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1